Efficacy of anti-seizure medications and alternative therapies (ketogenic diet, CBD, and quinidine) in KCNT1-related epilepsy: A systematic review.
Gras et al.·Epilepsia OpenImpact 3.1
GemischtGRADEHoch17 Zitate
Stichprobek = 43 Studien n = 197 Pat.
Dauerunklar
EndpunktAnfallsfrequenz/-intensität
Verblindungunklar
DesignSystematic Review
Cannabinoidcbd
”Kernaussage
Ketogene Diät, CBD und Chinidin zeigen in Untergruppen von Patienten mit KCNT1-bezogener Epilepsie Vorteile (KD 44,6–62,5%, CBD 50%, Chinidin 44,6%), während konventionelle Antiepileptika selten wirksam sind (5–25%).
Zusammenfassung
Systematische Review zu KCNT1-assoziierter Epilepsie; k=43 Studien, n=197 Patienten. CBD (inkl. Epidyolex) führte bei EIMFS-Patienten in 50% (6/12) zu einer Verbesserung der Anfallshäufigkeit oder -intensität; bei DEE-Patienten in 1/2 Fällen. Ketogene Diät und CBD werden als prüfenswerte Optionen bei therapieresistenter KCNT1-Epilepsie eingestuft; konventionelle Antiepileptika zeigten nur in 5–25% der Fälle Wirkung.
P
PopulationPatienten mit KCNT1-assoziierter Epilepsie (EIMFS, (AD)SHE, DEE), gepoolt n=197
I
InterventionKetogene Diät, Cannabidiol (CBD inkl. Epidyolex), Quinidine sowie konventionelle Antiepileptika
O
OutcomeKD Nutzen bei 62,5% der EIMFS-Patienten (25/40), CBD bei 50% (6/12), Quinidine bei 44,6% (25/56); bei (AD)SHE kein Nutzen für KD oder Quinidine; bei DEE: KD 4/7, CBD 1/2, Quinidine 6/9; konventionelle ASM selten wirksam (5–25%)
Vertrauen in die Evidenz
Sehr niedrigNiedrigModeratHoch
Hoch
Höchste von vier GRADE-Stufen, die Effektschätzung ist sehr verlässlich.
KCNT1-related epilepsies encompass three main phenotypes: (i) epilepsy of infancy with migrating focal seizures (EIMFS), (ii) autosomal dominant or sporadic sleep-related hypermotor epilepsy [(AD)SHE], and (iii) different types of developmental and epileptic encephalopathies (DEE). Many patients present with drug-resistant seizures and global developmental delays. In addition to conventional anti-seizure medications (ASM), multiple alternative therapies have been tested including the ketogenic diet (KD), cannabidiol (CBD-including Epidyolex and other CBD derivatives) and quinidine (QUIN). We aimed to clarify the current state of the art concerning the benefits of those therapies administered to the three groups of patients. We performed a literature review on PubMed and EMBase with the keyword "KCNT1" and selected articles reporting qualitative and/or quantitative information on responses to these treatments. A treatment was considered beneficial if it improved seizure frequency and/or intensity and/or quality of life. Patients were grouped by phenotype. A total of 43 studies including 197 patients were reviewed. For EIMFS patients (32 studies, 135 patients), KD resulted in benefit in 62.5% (25/40), all types of CBD resulted in benefit in 50% (6/12), and QUIN resulted in benefit in 44.6% (25/56). For (AD)SHE patients (10 studies, 32 patients), we found only one report of treatment with KD, with no benefit noted. QUIN was trialed in 8 patients with no reported benefit. For DEE patients (10 studies, 30 patients), KD resulted in benefit for 4/7, CBD for 1/2, and QUIN for 6/9. In all groups, conventional ASM are rarely reported as beneficial (in 5%-25% of patients). Ketogenic diet, CBD, and QUIN treatments appear to be beneficial in a subset of patient with drug-resistant epilepsy. The KD and CBD are reasonable to trial in patients with KCNT1-related epilepsy. Further studies are needed to identify optimal treatment strategies and to establish predictive response factors.